Sofpironium Bromide, 15% + Vehicle
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Axillary Hyperhidrosis
Conditions
Axillary Hyperhidrosis
Trial Timeline
Dec 4, 2020 → Aug 13, 2021
NCT ID
NCT03948646About Sofpironium Bromide, 15% + Vehicle
Sofpironium Bromide, 15% + Vehicle is a phase 3 stage product being developed by Botanix Pharmaceuticals for Axillary Hyperhidrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03948646. Target conditions include Axillary Hyperhidrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03948646 | Phase 3 | Completed |
Competing Products
9 competing products in Axillary Hyperhidrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| Azithromycin SR + Amoxiclav 1000 mg | Pfizer | Pre-clinical | 22 |
| azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin | Pfizer | Phase 3 | 76 |
| Telithromycin | Sanofi | Phase 3 | 76 |
| Azithromycin + Telithromycin | Sanofi | Approved | 84 |
| Avelox (Moxifloxacin, BAY12-8039) | Bayer | Approved | 82 |
| Sofpironium Bromide Gel, 15% + Vehicle | Botanix Pharmaceuticals | Phase 3 | 69 |
| Sofpironium Bromide Gel, 5% + Sofpironium Bromide Gel, 15% | Botanix Pharmaceuticals | Phase 3 | 69 |
| Sofpironium Bromide Gel, 15% | Botanix Pharmaceuticals | Phase 2 | 44 |